Fly News Breaks for February 21, 2018
ESPR
Feb 21, 2018 | 09:10 EDT
Needham analyst Chad Messer raised his price target on Esperion to $94 and kept his Strong Buy rating. Messer notes that regulatory uncertainty for the company is in the past, while the phase 3 readouts on its Bempedoic Acid products starting next month could disclose further progress toward a "blockbuster opportunity". The analyst says that the readouts are "significantly de-risked" given the lack of any safety signals to date.
News For ESPR From the Last 2 Days
There are no results for your query ESPR